Reaching Others University at Buffalo - The State University of New York
Skip to Content
Kate                           Rittenhouse-Olson

Kate Rittenhouse-Olson PhD

Department of Biotechnical and Clinical Laboratory Sciences

Professor, Director Biotechnology Undergraduate Program

 
top-left cornertop-right corner
Professional Summary:

My research for the last 22 years has focused on carbohydrate antigens that are important in cancer and in infectious disease (bacterial, viruses and parasites). These structures play important roles in the growth, adhesion and spread of cancer cells and bacteria and viruses. Immune responses to these structures can therefore be an effective mechanism to decrease disease. The anti-carbohydrate immune response is usually T cell independent, more difficult to develop and less in magnitude than the immune response to proteins.My long-term goals involve using information obtained about carbohydrates of related structures to manipulate the anti-carbohydrate immune response to improve clinical outcome. This work has involved use of synthetic oligosaccharides conjugated to bovine serum albumin as antigens, the use of structurally related synthetic oligosaccharides in inhibition studies, the use of antibody to carbohydrates in immunotherapy and immunolocalization of cancer, the use of genetic analysis of genes related to carbohydrate synthesis and adhesion, bacterial vaccine stability assays and bacteria rapid diagnosis assay development. The immunochemical aspects of this work were performed to determine the immunodominant regions of the sugars and the effects of small structural changes in the inhibitory oligosaccharides on the immunologic reaction.
I have been involved in research concerning the immune response to carbohydrate antigens since 1984, through experience gained while a post-doctoral fellow at Roswell Park Cancer Institute (RPCI), gaining clinical diagnostic experience with Dr. T. Ming Chu, (the discoverer of Prostate Specific Antigen for diagnosis) and then carbohydrate experience with Dr. Khushi Matta (Carbohydrate synthetic chemist). Since that time, I have been involved in the development of monoclonal and polyclonal antibodies to defined saccharides as diagnostic markers or as vaccine candidates in both bacterial and cancer research.

My laboratory, RPCI based for the first 9 years, and now at UB for the last 13 years, has had an emphasis on tumor associated carbohydrate antigens, and recently has been involved in 2 patent applications, “Use of anti-TF antibody to block metastasis of TF- antigen bearing tumors” (K R Olson, principle inventor of JAA-F11 monoclonal antibody), and “Carbohydrate Antigen-Nanoparticle Conjugates and Methods for Inhibiting Metastasis in Cancer” (K R Olson, co-inventor). Thomsen-Friedenreich antigen (TF-Ag) is a tumor associated antigen that is exposed in many types of carcinoma cells including breast, prostate, colon, and bladder.

Education and Training:
  • Cert, Immunology, A.S.C.P. (2002)
  • PhD, Microbiology, SUNY The University at Buffalo (1984)
  • MS, Microbiology/ Experimental Pathology, University of Kentucky (1980)
  • BS, SUNY Environmental Science and Forestry (1978)
Employment:
  • Professor, SUNY The University at Buffalo
  • Editor, Immunological Investigations
Awards and Honors:
  • Faculty Award for Excellence in Mentoring Undergraduates in Research and Cr (2011)
  • SUNY Downstate Keynote Speaker (2010)
  • King Saud University Gold Award for Service, Research (2009)
  • 2008 Life Sciences Inventor of the Year Third Place award (2009)
  • Gender Institute’s Distinguished Scholar Lecturer (2009)
  • Chancellor’s Award for Teaching Excellence (2008)
  • STOR Visionary Innovator (2006)

Grants and Sponsored Research:
  • May 2013–May 2014
    NYSTAR UB Center for Advanced Biomedical and Bioengineering Technology (UB CAT)
    NYSTAR
    Role: Principal Investigator
    $32,000
  • May 2013–April 2014
    Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy(1R41CA176951-01)
    NCI
    Role: Principal Investigator
    $282,222
  • March 2010–February 2013
    King Saud University Chairs Research Fund
    King Saud University
    Role: Principal Investigator
    $300,000
Patents:
  • THERAPEUTIC USE OF ANTI-TF-ANTIGEN ANTIBODY The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF--Ag, or for detection of tumors or metastatic foci which express TF--Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF--Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF--Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metastatic foci or tumors which comprise cancer cells expressing TF--Ag. Read more: http://www.faqs.org/patents/app/20080226561#ixzz1Is7RI9Ii

Journal Articles:
See All (26 Total) >

Presentations:
  • "Antibody to the Thomsen-Friedenreich Disaccharide to Block Cancer Metastasis" University of Georgia Complex Carbohydrate Research Center, University of Georgia Complex Carbohydrate Research Center (2011)
  • "Antibody to the Thomsen-Friedenreich Disaccharide to Block Cancer Metastasis" Emory (2011)
  • "Use of anti-TF-Ag to Block Metastasis." Malaysia Embassy, Malaysia Embassy, Malaysia Embassy (2011)
  • "Thomsen-Friedenreich antigen as a pancarcinoma vaccine target" . Novartis Vaccine Workshop, Novartis (2010)
  • "Carbohydrate Tumor Antigen Vaccines using Unique Strategies" Cambridge Healthtech Institute (CHI) Conference Novel Vaccines: Design & Development, Cambridge Healthtech Institute, Novel Vaccines: Design & Development (2010)
  • "Anti-TF-Ag, in vivo and in vitro specificity, potential for cancer therapy" Workshop on Recognition of host and pathogen glycans by mammalian GBPs and Mammalian GBPs in immune cell communication, CFG, Consortium for Functional Glycomics (2010)
  • "Breast Cancer Studies: Multiple Approaches in Development of a Vaccine Against a Promising Cancer Carbohydrate Target" . Downstate Medical Center Research Day, SUNY DOwnstate, SUNY Downstate (2010)
  • "Antibody to a promising breast cancer carbohydrate: Therapeutic potential" Beijing Medical School, Capital Medical School, Capital Medical School (2010)
  • "Using Antibody to Target a Carbohydrate Breast Tumor Antigen in Attempts to Improve Prognosis." RPCI Immunology Meeting, RPCI, RPCI Immunology (2010)
  • "Carbohydrate Tumor Antigen Vaccines using Unique Strategies." Glyco XX,, Society of Glycobiology, Glycobiology (2009)
  • "Cancer Studies: Collaborative Research towards Innovative Therapies" King Saud University, King Saud University, King Saud University (2009)
See All (11 Total) >

Clinical Specialties:
Clinical Offices:
Insurance Accepted:

bottom-left cornerbottom-right corner

Contact Information

44 Cary Hall
Buffalo, NY 14214
Email: krolson@buffalo.edu


Log in to Update Your Profile
"); pageTracker._trackPageview();